Highlands Oncology Group (North Hills)
Fayetteville, AR
Accepting patients
TRIlogy-5
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
- Trispecific Antibody
- T Cell Engager (TCE)
- GPRC5D
- BCMA
- Randomization
- Phase 3